Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma Lenalidomide Plus Rituximab Ups Response in Relapsed Indolent Lymphoma
In patients with relapsed or refractory indolent non-Hodgkin lymphoma, adding lenalidomide to rituximab improves response, according to a placebo-controlled trial.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
More News: Allergy | Allergy & Immunology | Cancer & Oncology | Hematology | Lymphoma | Non-Hodgkin's Lymphoma | Revlimid | Rituxan